Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline
Open accessThe DOI matches its Crossref record; 204 of the 206 references it cites were found in a registry or an index; 68 of the 244 sources its claims cite were checked for support.
Abstract
Objective The aim was to develop clinical practice guidelines on hypertriglyceridemia. Participants The Task Force included a chair selected by The Endocrine Society Clinical Guidelines Subcommittee (CGS), five additional experts in the field, and a methodologist. The authors received no corporate funding or remuneration. Consensus process Consensus was guided by systematic reviews of evidence, e-mail discussion, conference calls, and one in-person meeting. The guidelines were reviewed and approved sequentially by The Endocrine Society's CGS and Clinical Affairs Core Committee, members responding to a web posting, and The Endocrine Society Council. At each stage, the Task Force incorporated changes in response to written comments. Conclusions The Task Force recommends that the diagnosis of hypertriglyceridemia be based on fasting levels, that mild and moderate hypertriglyceridemia (triglycerides of 150-999 mg/dl) be diagnosed to aid in the evaluation of cardiovascular risk, and that severe and very severe hypertriglyceridemia (triglycerides of > 1000 mg/dl) be considered a risk for pancreatitis. The Task Force also recommends that patients with hypertriglyceridemia be evaluated for secondary causes of hyperlipidemia and that subjects with primary hypertriglyceridemia be evaluated for family history of dyslipidemia and cardiovascular disease. The Task Force recommends that the treatment goal in patients with moderate hypertriglyceridemia be a non-high-density lipoprotein chole…
Overview
CoChat Summary
TL;DR
This Endocrine Society clinical practice guideline recommends evaluating and treating hypertriglyceridemia with fasting triglyceride measurement, secondary-cause workup, lifestyle therapy for mild-to-moderate elevations, and combined diet plus drug therapy for severe/very severe hypertriglyceridemia to prevent pancreatitis. It also concludes that triglycerides are associated with cardiovascular risk but whether they are causal remains uncertain.
Key findings
- The guideline recommends screening adults with a fasting lipid panel at least every 5 yr (1/QQEE), basing hypertriglyceridemia diagnosis on fasting rather than nonfasting triglycerides (1/QQQE), and against routine lipoprotein particle heterogeneity measurement (1/QQEE).
- It defines moderate hypertriglyceridemia as 200–999 mg/dl, severe as 1000–1999 mg/dl, and very severe as ≥2000 mg/dl; for severe/very severe hypertriglyceridemia (>1000 mg/dl), it recommends combining dietary fat and simple carbohydrate reduction with drug treatment to reduce pancreatitis risk (1/QQQQ), with fibrate as first-line for triglyceride-induced pancreatitis (1/QQQE).
- Lifestyle therapy is recommended initially for mild-to-moderate hypertriglyceridemia (1/QQEE); for moderate hypertriglyceridemia, the treatment goal is a non-HDL cholesterol level in agreement with NCEP ATP guidelines (1/QQEE); statins should not be used as monotherapy for severe or very severe hypertriglyceridemia but may be useful for moderate hypertriglyceridemia to modify cardiovascular risk (1/QQEE).
- In NHANES 1999–2004, 33% of nearly 6000 participants had serum triglycerides ≥150 mg/dl (42% among those aged ≥60 yr); about 14% had 150–200 mg/dl, 16% had 200–500 mg/dl, and about 2% had >500 mg/dl. Meta-analytic estimates included an adjusted odds ratio of 1.72 (95% CI, 1.56–1.90) for coronary heart disease comparing top vs bottom triglyceride tertiles, and an ERFC hazard ratio of 1.37 (95% CI, 1.31–1.42) after adjustment for nonlipid factors, reduced to 0.99 (95% CI, 0.94–1.05) after adjustment for HDL and non-HDL cholesterol.
Methods
- The Task Force followed the GRADE approach: strong recommendations use “we recommend” and number 1; weak recommendations use “we suggest” and number 2; evidence quality is denoted QEEE (very low), QQEE (low), QQQE (moderate), and QQQQ (high).
- The guideline was developed by a chair selected by The Endocrine Society Clinical Guidelines Subcommittee, five additional experts, and a methodologist; evidence included observational/epidemiological studies and a systematic review/meta-analysis commissioned by The Endocrine Society.
- Funding was derived solely from The Endocrine Society, and the Task Force received no corporate funding or remuneration.
Limitations
- The Task Force states that it acknowledges the observational nature of the available evidence and dependence on epidemiological studies, and that it made several strong recommendations based on assumptions about patients’ values and preferences.
- The paper states that whether serum triglycerides are causally related to atherosclerosis remains to be elucidated, that elevated triglycerides may sometimes be a marker rather than a causal factor, and that there is a lack of clear human data showing triglyceride reductions reduce cardiovascular disease.
- Stated limitations of specific evidence include lack of standardization and reference levels for nonfasting triglycerides, and for the Copenhagen City Heart Study analysis, a small number of subjects with high triglycerides, no adjustment for HDL cholesterol, and lack of fasting triglyceride levels for comparison.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
53 Valid · 24 Not valid · 106 Not checked · 100 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Epidemiological studies vary as to the independent association between large or small LDL and atherosclerotic cardiovascular disease (30).”
§ Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline > 1.3. Evidence
What the sources say
- Partly supportedcites [30] Austin, 1990, Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk., Circulation sourceExperimental — accuracy not yet measured
The introduction (p. 495) reports that the small, dense LDL phenotype was associated with increased myocardial infarction risk, consistent with two previous studies. But the paper does not say that epidemiological studies vary in their findings about an independent association of large or small LDL with cardiovascular disease. Its multivariate analysis examines associations with LDL phenotype, not independent associations with disease. (LLM, conf=0.82)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Prospective multivariate studies demonstrate that large LDL predicts atherosclerosis and coronary heart disease (35,38,39).”
§ Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline > 1.3. Evidence
What the sources say
- Not checked — no full text of the sourcecites [35] Sacks, 2003, Low density lipoprotein and cardiovascular disease: a reappraisal. (Clinical Review 163)., J Clin Endocrinol Metab source
- Partly supportedcites [38] Mora, 2009, Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women., Circulation sourceExperimental — accuracy not yet measured
The Results (Association of NMR Lipoproteins, Lipids, and Apolipoproteins with CVD; page unavailable) report that large LDL particles were significantly associated with incident cardiovascular disease in women when all nine particle subclasses were included in the model. They were not associated with cardiovascular disease in the separate adjusted model. The paper does not establish that large LDL specifically predicts atherosclerosis or coronary heart disease. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [39] Campos, 2001, Low density lipoprotein size, pravastatin treatment, and coronary events., JAMA source
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Several reports also show that measurement of apoB is superior to measurement of LDL or even non-HDL cholesterol as an indicator of global CVD risk (40,41).”
§ Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline > 1.3. Evidence
What the sources say
- Not checked — no full text of the sourcecites [40] de Graaf, 2008, A diagnostic algorithm for the atherogenic apolipoprotein B dyslipoproteinemias., Nat Clin Pract Endocrinol Metab source
- Supportedcites [41] Holewijn, 2010, Apolipoprotein B, non-HDL cholesterol and LDL cholesterol for identifying individuals at increased cardiovascular risk., J Intern Med source
The Discussion reports that, in this population-based sample, apoB identified people with a compromised cardiovascular risk profile more effectively than non-HDL cholesterol, while LDL cholesterol was least effective. It also reports significantly greater discrimination of prevalent CVD for apoB than for non-HDL cholesterol. The finding is based on this cohort; the authors note that a cited meta-analysis found no difference between apoB and non-HDL cholesterol. (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Several prospective studies suggest that circulating levels of small, dense LDL particles are better predictors of coronary atherosclerosis, carotid atherosclerosis, and response to therapy than are levels of large, buoyant LDL particles (28,(31)(32)(33).”
§ Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline > 1.3. Evidence
What the sources say
- Partly supportedcites [28] Zambon, 1999, Evidence for a new pathophysiological mechanism for coronary artery regression: hepatic lipase-mediated changes in LDL density., Circulation sourceExperimental — accuracy not yet measured
The Abstract reports prospective associations between LDL size or density and coronary artery disease, and says patients with small, dense LDL responded better to therapy than those with large, buoyant LDL. The Results link changes in LDL buoyancy to changes in coronary stenosis. The cited paper does not address carotid atherosclerosis, so it does not support that part of the claim. Page numbers are unavailable in our copy. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [31] St-Pierre, 2005, Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Québec Cardiovascular Study., Arterioscler Thromb Vasc Biol source
- Not checked — no full text of the sourcecites [32] Mora, 2007, LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA)., Atherosclerosis source
- Partly supportedcites [33] Musunuru, 2009, Ion mobility analysis of lipoprotein subfractions identifies three independent axes of cardiovascular risk., Arterioscler Thromb Vasc Biol sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) reports that small and medium LDL particle levels were associated with cardiovascular disease, whereas large LDL particle levels were not significantly related; it also says this pattern agrees with prospective cohorts including a study of carotid atherosclerosis. It does not establish that small, dense LDL levels predict response to therapy better than large LDL levels. Instead, the Discussion proposes evaluating lipoprotein measures in treatment studies as future work. (LLM, conf=0.84)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Prospective studies have indicated that, compared with fasting levels, nonfasting serum triglyceride levels may be a better or similar predictor of CVD events in the general population (15-18).”
§ Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline > 1.2. Evidence
What the sources say
- Not checked — no full text of the sourcecites [15] Nordestgaard, 2007, Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women., JAMA source
- Not checked — no full text of the sourcecites [16] Bansal, 2007, Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women., JAMA source
- Supportedcites [17] Mora, 2008, Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events., Circulation source
The paper’s introductory passage says three studies suggested that nonfasting triglycerides may predict CVD events better than or similarly to fasting levels. Its Results also report a stronger association for nonfasting triglycerides in its prospective cohort of initially healthy women. No page number is available in our copy. (LLM, conf=0.91)
- Not checked — no full text of the sourcecites [18] Stalenhoef, 2008, Association of fasting and nonfasting serum triglycerides with cardiovascular disease and the role of remnant-like lipoproteins and small, dense LDL., Curr Opin Lipidol source
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
149 more claims · 26 with their cited sources checked
Create a free account to see all 283 claims and to verify the 1 reference still open.
- Probably not a substantial claim. 53
- It may state two separate claims as one. 94
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“HTG may result from impaired clearance of TRLs, most often due to pathogenic variants in the lipolytic pathway, ranging from monogenic defects in LPL gene or its cofactors (APOC2, APOA5, LMF1, and GPIHBP1) to polygenic susceptibility, and may be exacerbated by secondary factors such as diabetes, obesity, alcohol use, and certain medications [5, 6].”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Current management strategies for HTG and mixed dyslipidemia provide limited and inconsistent benefits in TG lowering and cardiovascular outcomes, underscoring the need for more effective and durable approaches targeting TRL and apoB-containing lipoproteins (Filtz et al., 2024; Berglund et al., 2012; Chapman et al., 2011).”
From Efficacy and safety of small interfering RNA (siRNA) therapies for hypertriglyceridemia and mixed dyslipidemia: an updated systematic review and meta-analysis (2026) · cites this paper as Berglund et al., 2012
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“A delay in diagnosis may place patients at an increased risk for acute pancreatitis.11”
From Familial chylomicronemia syndrome: Bringing to life dietary recommendations throughout the life span (2018) · cites this paper as [11]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The APPROACH trial showed that volanesorsenmediated lowering of plasma apolipoprotein C-III levels in patients with familial chylomicronemia syndrome effectively lowered plasma triglycerides below the threshold of 750 to 880 mg per deciliter”
From Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome (2019) · cites this paper as [22]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Acute pancreatitis can lead to chronic pancreatitis, 10,11 signs of exocrine or endocrine pancreatic insufficiency, including pancreatic (type 3c) diabetes, 12 and can be fatal.”
From Familial chylomicronemia syndrome: Bringing to life dietary recommendations throughout the life span (2018) · cites this paper as [11]
Experimental — accuracy not yet measured
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline > 1.1. Evidence
“Of subjects with hypertriglyceridemia, about 14% had mild hypertriglyceridemia (150 -200 mg/dl), whereas 16% had triglyceride levels of 200 -500 mg/dl, and about 2% had levels above 500 mg/dl.”
§ Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline > 1.1. Evidence
“In the National Health and Nutrition Examination Survey (NHANES), 1999 -2004, 33% of the nearly 6000 participants (37% men, 30% women) had serum triglycerides of at least 150 mg/dl (Ն1.7 mmol/liter) (5).”
Citations
Cites
Alberti, K. G. M. M., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., Fruchart, J.-C., James, W. P. T., Loria, C. M., & Smith, S. C. (2009) · Circulation · doi:10.1161/circulationaha.109.192644 · Cited by 14,860 · cited 7×
“Cosponsoring Associations: American Heart Association, European Society of Endocrinology.”
InfluentialDetection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., Smith, S. C., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.169404 · Cited by 11,961
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“The Task Force followed the approach recommended by the Grading of Recommendations, Assessment, Development, and Evaluation group (1).”
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
Research works printed but not linked: 2
- Assmann, 1993, Results and conclusions of the prospective cardiovascular Munster (PROCAM) study, 19
- Brunzell, 2001, Familial lipoprotein lipase deficiency, ApoC-II deficiency, and hepatic lipase deficiency, 2789
Cited by
Items 401–500 of 886
Li, Z., Lai, J., Wen, L., Chen, Q., Tan, R., Zhong, X., Liu, Y., & Liu, Y. (2023) · Biological Trace Element Research · doi:10.1007/s12011-023-03608-0 · Cited by 11
Contemporary and Novel Therapeutic Options for Hypertriglyceridemia
Bell, D. A., & Watts, G. F. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.08.001 · Cited by 10
Neonatal hyperlipidemia with pancreatitis
Shah, M., Roshan, R., Desai, R., & Kadam, S. (2018) · Journal of Postgraduate Medicine · doi:10.4103/jpgm.jpgm_731_17 · Cited by 9
Effect of Interaction between Early Menarche and Genetic Polymorphisms on Triglyceride
Lee, H., Leem, S., Oh, B., & Park, T. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/9148920 · Cited by 10
“TG levels correlatively increase during pregnancy with estrogen-induced stimulated secretion of hepatic TG-rich lipoprotein [36].”
BackgroundMayerhofer, C., Speckmann, C., Kapp, F., Teufel‐Schäfer, U., Kluwe, W., Schneider, J., & Flotho, C. (2020) · Pediatric Hematology and Oncology · doi:10.1080/08880018.2020.1756999 · Cited by 9
Apheresis Technique for Acute Hyperlipidemic Pancreatitis: A Systemic Review and Meta-Analysis
Lin, Y.-F., Yao, Y., Xu, Y., & Huang, H. (2022) · Digestive Diseases and Sciences · doi:10.1007/s10620-022-07545-1 · Cited by 9
“HTGP accounts for 1–10% of cases of AP [2], and 12–38% of these patients may develop severe HTGP [3].”
BackgroundFachin, A., Carlo, C. D., Maestro, A., Zanon, D., Barbi, E., & Maximova, N. (2023) · Pharmaceuticals · doi:10.3390/ph16081069 · Cited by 8
“The Endocrine Society further specifies, defining values of 2000 mg/dL as very severe hypertriglyceridemia [18].”
BackgroundDysbetalipoproteinemia: Two cases report and a diagnostic algorithm
Kei, A. A., Miltiadous, G., Bairaktari, E., Hadjivassiliou, M., Cariolou, M., & Elisaf, M. (2015) · World Journal of Clinical Cases · doi:10.12998/wjcc.v3.i4.371 · Cited by 11
Olanzapine-Induced Hypertriglyceridemia Resulting in Necrotizing Pancreatitis
Buszek, S. M., Roy‐Chaudhury, P., & Yadlapalli, G. (2016) · ACG Case Reports Journal · doi:10.14309/crj.2016.77 · Cited by 10
CE: Triglycerides Do They Matter?
Scordo, K. A., & Pickett, K. A. (2016) · AJN American Journal of Nursing · doi:10.1097/01.naj.0000511539.37103.0b · Cited by 11
Copeland, L. A., Swendsen, C. S., Sears, D. M., MacCarthy, A. A., & McNeal, C. J. (2018) · PLoS ONE · doi:10.1371/journal.pone.0179998 · Cited by 10
Diabetic dyslipidemia with eruptive xanthoma
Hsueh, Y.-C., Chou, C.-L., & Lee, T.-I. (2019) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.86a.18104 · Cited by 9
Semenkovich, C. F., Goldberg, A. C., & Goldberg, I. J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-29738-7.00037-x · Cited by 23
Self-citationDiretriz Brasileira de Dislipidemias e Prevenção da Aterosclerose – 2025
Rached, F. H., Miname, M. H., Rocha, V. Z., Zimerman, A., Cesena, F. Y., Sposito, A. C., Santos, R. D., Behr, P. E. B., Bianco, H. T., Alves, R. J., et al. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20250640 · Cited by 97
Prevention and treatment of hypertriglyceridemia-mediated acute pancreatitis: A narrative review
Subramanian, S., Soran, H., Kessler, A. S., McClain, M. R., Eckel, R. H., & Rosenson, R. S. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.106648 · Cited by 13
Genetic Lipid Disorders Associated with Atherosclerotic Cardiovascular Disease
Mszar, R., Webb, G., Kulkarni, V., Ahmad, Z., & Soffer, D. E. (2022) · Medical Clinics of North America · doi:10.1016/j.mcna.2021.11.009 · Cited by 8
Sex-Specific Cardiometabolic Determinants of Postoperative Atrial Fibrillation After Cardiac Surgery
Paquin, A., Voisine, P., Poirier, P., Clavel, M.-A. A., O'Connor, S. E., Roberge, J., & Piché, M. (2024) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2024.02.002 · Cited by 8
Rabbani, B., Moghadam, M. A., Esmaeili, S., Rabbani, A., Akbari, B., & Mahdieh, N. (2024) · International Journal of Genomics · doi:10.1155/2024/6653857 · Cited by 8
“According to Endocrine Society, we here de fi ne HTG as normal ( > 150), mild (150-199), moderate (200-999), severe (1000-1999), and very severe ( 2000) form of HTG [4].”
BackgroundTominaga, T., Matsushima, M., Nagata, T., et al. (2015) · BMC Family Practice · doi:10.1186/s12875-015-0272-3 · Cited by 8
“Those with mild abnormality were not in the stage that would generally require immediate treatment at medical consultations in Japan, but had borderline high values that require attention according to NCEP-ATP III and AHA guidelines [11,18,19].”
MethodHipertrigliceridemia grave. Características clínicas y manejo terapéutico
Masson, W. M., Rossi, E., Siniawski, D. A., Damonte, J. I., Halsband, A., Barolo, R., & Scaramal, M. (2018) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2018.03.005 · Cited by 16
Diabetic Ketoacidosis and the Domino Effect
Shaikh, B., Sohaib, M., Alshantti, R., Barrera, F., Faridi, F., & Murvelashvili, N. (2018) · American Journal of Case Reports · doi:10.12659/ajcr.911747 · Cited by 8
“Serum triglyceride levels above 1000 mg/dL are most frequently implicated [3].”
BackgroundMarcotte, B. V., Allaire, J., Guénard, F., de Toro‐Martín, J., Couture, P., Lamarche, B., & Vohl, M. (2020) · Genes & Nutrition · doi:10.1186/s12263-020-00669-x · Cited by 9
Donato, L. J., & Meeusen, J. W. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-815499-1.00028-4 · Cited by 9
Hypertriglyceridemia as an Independent Predictor for Ten-Year Incidence of Diabetes in Thais
Charoensri, S., Turnsaket, S., & Pongchaiyakul, C. (2021) · Vascular Health and Risk Management · doi:10.2147/vhrm.s326500 · Cited by 11
Insulin Treatment of Hypertriglyceridemia During Pregnancy
Cheng, D., Su, Y., Li, F., & Xu, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.785756 · Cited by 7
“Although no significant side effects have been observed in case reports of fibrates (gemfibrozil), which is classified as category C drugs by the Food and Drug Administration (FDA), and niacin supplementation in early and mid-pregnancy, they are still left to be controversial, and further research is required to assis…”
BackgroundManagement of Mild-to-Moderate Hypertriglyceridemia
Pulipati, V. P., Brinton, E. A., & Hatipoğlu, B. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.07.003 · Cited by 12
Sánchez-Vinces, S., Garcia, P. H. D., Silva, A., Fernandes, A. M. A. P., Barreto, J. A., Duarte, G. H. B., Antônio, M. A., Birbrair, A., Porcari, A. M., & Carvalho, P. D. O. (2023) · Metabolites · doi:10.3390/metabo13020222 · Cited by 11
“These lipid alterations are frequently associated with increased cardiovascular risk [3] and with the etiopathogenesis of several cardiometabolic disorders, such as diabetes [4], liver steatosis [5], and pancreatitis [6].”
BackgroundHypertriglyceridemia-Induced Acute Pancreatitis
Park, J. M. (2017) · The Korean Journal of Pancreas and Biliary Tract · doi:10.15279/kpba.2017.22.4.158 · Cited by 8
Severe Familial Hypertriglyceridemia: Successful Treatment With Insulin and a Modified Meal Plan
Ayyavoo, A., Raghupathy, P., Agarwal, M., & Hofman, P. L. (2018) · Journal of the Endocrine Society · doi:10.1210/js.2018-00299 · Cited by 8
Irie, S., Anno, T., Kawasaki, F., Shigemoto, R., Nakanishi, S., Kaku, K., & Kaneto, H. (2019) · BMC Endocrine Disorders · doi:10.1186/s12902-019-0425-9 · Cited by 8
“Hypertriglyceridemia is a common clinical diagnosis and sometimes classified as primary or secondary one [2].”
BackgroundTargets in osteoporosis treatment.
Bandeira, F. A. F., de Paula, F. J. A., Lazaretti‐Castro, M., & Premaor, M. O. (2014) · PubMed · Cited by 8
Thanh, N. H., Nhi, P. Y., Huyen, N. T., et al. (2024) · Indian Journal of Gastroenterology · doi:10.1007/s12664-024-01669-0 · Cited by 7
“The treatment for this condition includes conventional measures such as fluid resuscitation, fasting, pain control and TG-lowering therapy, which consists of insulin infusion, plasma exchange and fibrate [3].”
Beyond the Guidelines: Perspectives on Management of Pediatric Patients with Hypertriglyceridemia
Gagnon, C. A., & Ashraf, A. P. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01237-z · Cited by 10
“The Endocrine Society (2012) guidelines classify mild HTG as 150–199 mg/dL, moderate HTG as 200-999 mg/dL, severe HTG as 1000–1999 mg/ dL, and very severe HTG as 2000 mg/dL or higher [13”
BackgroundKenkre, J. S., Mazaheri, T., Neely, R. D. G., Soran, H., Datta, D. B. N., Penson, P. E., Downie, P., Yates, A. M., Hayden, K., Patel, M., et al. (2025) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/00045632251315303 · Cited by 10
Dyslipidemia in Children and Adolescents: Current Insights and Updated Treatment Approaches
Kim, S. E. (2025) · Pediatric Gastroenterology Hepatology & Nutrition · doi:10.5223/pghn.2025.28.3.148 · Cited by 13
“However, clinical studies on this treatment are still limited [37,38].”
Eruptive Xanthomas Precipitated by Severe Hypertriglyceridemia From Diabetes and Alcohol Use
Munoz, N. R., Agwuegbo, C. C., & Gauhar, F. (2023) · Cureus · doi:10.7759/cureus.43288 · Cited by 8
“Triglycerides greater than 1,000 mg/dL are considered severe hypertriglyceridemia and are a high risk for pancreatitis [3].”
BackgroundPu, W., Tang, W., Shen, Y., Ji, F., Huang, J., Liu, Y., Zhou, J., & Yin, G. (2023) · Pancreatology · doi:10.1016/j.pan.2023.10.003 · Cited by 8
Çelik, M. Y., Canda, E. E., Yazıcı, H., Erdem, F., Yanbolu, A. Y., Altınok, Y. A., Parıltay, E., Akın, H., Uçar, S. K., & Çöker, M. (2024) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2024.02.006 · Cited by 7
Wen, S., Zhang, Y., Zhao, G., Tu, Z., Zhang, K., & Cui, Y. (2024) · Medicine · doi:10.1097/md.0000000000038265 · Cited by 8
“…III guidelines of the National Cholesterol Education Program and the Endocrine Society all consider normal TG to be 1.7 mmol/L, and values above that are considered HTG. [14,15] Patients with AP were categorized into HTG and normal groups based on whether their TG levels exceeded 1.7 mmol/L.”
InfluentialHepburn, K. S., & Brzozowska, M. M. (2016) · BMJ Case Reports · doi:10.1136/bcr-2016-215413 · Cited by 9
McLaughlin, D. C., Fang, D. C., Nolot, B. A., et al. (2018) · Indian Journal of Nephrology · doi:10.4103/ijn.ijn_201_17 · Cited by 7
“included in the management recommendations of the 2012 Endocrine Society Clinical Practice Guidelines for hypertriglyceridemic pancreatitis[13] and is currently only a Category III (i.”
BackgroundUpala, P., Apidechkul, T., Wongfu, C., Khunthason, S., Kullawong, N., Keawdounglek, V., Chomchoei, C., Yeemard, F., & Tamornpark, R. (2021) · BMC Public Health · doi:10.1186/s12889-021-10632-z · Cited by 9
“7% among white American men and women, respectively [30], and 17.”
BackgroundChildhood Hypertriglyceridemia: Is It Time for a New Approach?
Sunil, B., & Ashraf, A. P. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01000-2 · Cited by 9
Liu, L., Hou, X., Song, A., Guan, Y., Tian, P., Wang, C., Ren, L., Tang, Y. P., Gao, L., Xing, X., et al. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13867 · Cited by 9
Wang, N., Guo, H., Jing, Y., Zhang, Y., Sun, B., Pan, X., Chen, H., Xu, J., Wang, M., Chen, X., et al. (2023) · Journal of Diabetes · doi:10.1111/1753-0407.13375 · Cited by 9
“Maternal lipid profile of TG, HDL-C, and LDL-C were increased within a physiological range from the second to third trimester during pregnancy 27 ; however, an independent relationship emerged between over-range lipid profile and fetal overgrowth, 10 including the level of TG at late pregnancy.”
BackgroundIsotretinoin Induced Pancreatitis
Dhattarwal, N., Khunger, N., & Lal, A. (2022) · Indian Journal of Dermatology · doi:10.4103/ijd.ijd_206_22 · Cited by 7
Effect of Plasma Exchange Treatment in Patients with Hypertriglyceridemia-Induced Acute Pancreatitis
Nguyen, D. C., Nguyễn, N. Á., Dinh, Q. K., Le, T. D., Vu, T. B., & Hoang, V. T. (2023) · Medicina · doi:10.3390/medicina59050864 · Cited by 10
“3 mmol/L and other causes were excluded [3,25].”
BackgroundLee, I., Tong, S., Hatada, M., Masterson, A. N., Hiraka, K., Okuda‐Shimazaki, J., Tsugawa, W., Hughes, G., & Sode, K. (2023) · Sensors and Actuators Reports · doi:10.1016/j.snr.2023.100164 · Cited by 5
Eruptive xanthoma associated with hypertriglyeridaemia and diabetes
Zhao, C., & Li, H. (2023) · Australian Journal of General Practice · doi:10.31128/ajgp-10-22-6587 · Cited by 7
Cumulative exposure to hypertriglyceridemia and risk of type 2 diabetes in young adults
Lee, M., Han, K., Kim, B., Kim, J.-D., Kim, M. J., Kim, B., Heo, J., Ahn, J., Sohn, S. Y., & Lee, J.-H. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111109 · Cited by 8
Drug treatment of dyslipidemia
Kim, S. (2016) · Journal of Korean Medical Association · doi:10.5124/jkma.2016.59.5.366 · Cited by 7
Chatterjee, S. (2018) · Diabetes & Obesity International Journal · doi:10.23880/doij-16000180 · Cited by 7
Sawalha, K., Kunnumpurath, A., & Kamoga, G. (2020) · Journal of Investigative Medicine High Impact Case Reports · doi:10.1177/2324709620940492 · Cited by 7
Qi, Y., Li, Y., Wang, Z., Wang, X., Meng, H., Li, W., Chen, D.-C., Li, M., Liu, J., & An, S. (2021) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-021-00626-7 · Cited by 7
Management of Hypertriglyceridemia-Induced Acute Pancreatitis in a Nondiabetic Patient
Reed, J. M., Hogan, B. M., Nasser‐Ghodsi, N., & Loftus, C. G. (2021) · Mayo Clinic Proceedings Innovations Quality & Outcomes · doi:10.1016/j.mayocpiqo.2020.08.015 · Cited by 7
Clinical Assessment of the Patient with Overweight or Obesity
Crane, J. D., & McGowan, B. M. (2017) · Endocrinology · doi:10.1007/978-3-319-47685-8_19-1 · Cited by 9
Clinical Lipidology and the Prevention of Vascular Disease: Time for Personalized Therapy
Brown, W. V. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1127 · Cited by 8
Gao, X., Gao, C., Fang, X., et al. (2025) · BMC Anesthesiology · doi:10.1186/s12871-025-03025-x · Cited by 6
“Hypertriglyceridemia included mild, moderate and severe hypertriglyceridemia with the diagnostic criteria of serum triglyceride concentration between 1.7 and 2.3 mmol/L, between 2.3 and 11.2 mmol/L and above 11.2 mmol/L, respectively [16].”
InfluentialHypertriglyceridemic pancreatitis: perspectives from China
Fan, Z., Li, J., & Wu, D. (2025) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000001123 · Cited by 11
Peterson, A. L. H., Ashraf, A. P., Bachman, J., Hegele, R. A., Rashad, M., South, A. M., Tran, A. H., Zachariah, J. P. V., & Wong, J. P. (2026) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atv.0000000000000195 · Cited by 8
Kedia, A. W., & Lynch, E. (2015) · Postgraduate Medicine · doi:10.1080/00325481.2015.1100086 · Cited by 6
“Notably, the Residual Risk Reduction Initiative and the Clinical Practice Guideline on Hypertriglyceridemia of the Endocrine Society recommend treatment with adjunctive medications to reduce cardiovascular risk.[3,5] High-dose omega-3 fatty acids are among the TG-lowering treatment options that may be administered on…”
BackgroundVitamin D Supplementation Reduces Hyperlipidemia and Improves Bone Mass in Pediatric Obesity
Wang, F., Bei, L., Zhang, X., & Fu, Y. (2024) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.2024052129 · Cited by 7
Cardiometabolic Impact of Non-Statin Lipid Lowering Therapies
Goyal, P., Igel, L. I., LaScalea, K., & Borden, W. B. (2014) · Current Atherosclerosis Reports · doi:10.1007/s11883-013-0390-0 · Cited by 7
Ongoing challenges for pharmacotherapy for dyslipidemia
Pisaniello, A. D., Scherer, D. J., Kataoka, Y., & Nicholls, S. J. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.986094 · Cited by 6
“These data have been embraced by treatment guidelines that recommend minimum dietary consumption of omega-3 fatty acids for prevention of cardiovascular disease [62,63].”
MethodGLP-1 Agonist Use in a Patient With an Explainable Cause of Pancreatitis
Brady, S. M., Kane, M. P., & Busch, R. S. (2015) · AACE Clinical Case Reports · doi:10.4158/ep15658.cr · Cited by 7
Consensus statement on the management of dyslipidaemias in adults
Béliard, S., Bonnet, F., Bouhanick, B., Bruckert, É., Cariou, B., Charrière, S., Durlach, V., Moulin, P., Valéro, R., & Vergès, B. L. (2017) · Annales d Endocrinologie · doi:10.1016/j.ando.2016.11.001 · Cited by 5
The Genetic Spectrum of Familial Hypertriglyceridemia in Oman
Al-Waili, K., Al‐Rasadi, K., Al-Bulushi, M., Habais, M., Al-Mujaini, A. S., Al-Yaarubi, S., Rimbert, A., Zadjali, R., Khaniabadi, P. M., Al-Barwani, H., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.886182 · Cited by 6
Ramírez‐Jiménez, A. K., Luzardo‐Ocampo, I., Cuéllar-Núñez, M. L., Anaya‐Loyola, M. A., León‐Galván, M. F., & Loarca-Piña, G. F. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.890136 · Cited by 8
“(2) After monocyte rolling mediated by E-selectin and receptor ESL-1, (3) the lower levels of VCAM-1 found in the microarray analysis, and predicted reductions in plasma LDL levels, reduce endothelial cell adhesion.”
BackgroundInfluentialKrauß, L. U., Brosig, A. M., Schlosser, S., Pavel, V., Mehrl, A., Gülow, K., Kandulski, A., Müller, M., & Schmid, S. A. (2023) · Digestive Diseases · doi:10.1159/000529975 · Cited by 10
Vitale, R. J., & Laffel, L. M. (2023) · JCEM Case Reports · doi:10.1210/jcemcr/luad046 · Cited by 7
“There are multiple diets which can contribute to hypertriglyceridemia, including those high in saturated fat, which may be seen in people eating low-carbohydrate or “keto” diets, and those high in sugar or refined carbohydrates, which are increasingly common in the developed world [10].”
BackgroundYazan, C. D. (2023) · Acta Endocrinologica (Bucharest) · doi:10.4183/aeb.2023.125 · Cited by 6
Sell, J. K., & Nunez, J. J. (2023) · Oxford University Press eBooks · doi:10.1093/med/9780197679098.003.0039 · Cited by 6
Lim, T. H., Orija, I. B., & Pearlman, B. L. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.11.2831 · Cited by 6
“Other secondary causes of hyperlipidemia most likely encountered in clinical practice include pregnancy, end-stage renal disease, nephrotic syndrome, hypothyroidism, excessive alcohol consumption, obstructive liver disease, and medications (in particular, thiazide diuretics, β-blockers, corticosteroids, oral contracep…”
BackgroundLa complejidad clínica de las hipertrigliceridemias severas y las unidades de lípidos
Pintó, X. (2013) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2013.01.003 · Cited by 7
Severe Hypertriglyceridemia‐Related Acute Pancreatitis: Myth or Reality?
Stefanutti, C., Labbadia, G., & Morozzi, C. (2013) · Therapeutic Apheresis and Dialysis · doi:10.1111/1744-9987.12063 · Cited by 6
Management of severe hypertriglyceridaemia
Cybulska, B., & Kłosiewicz−Latoszek, L. (2013) · Kardiologia Polska · doi:10.5603/kp.2013.0254 · Cited by 7
Liu, J., Lu, R., Wang, Y., Hu, Y., Jia, Y., Yang, N., Fu, J. H., & Wang, G. (2016) · PPAR Research · doi:10.1155/2016/6232036 · Cited by 6
“7mmol/L according to the guideline of NCEP ATP III and the Endocrine Society [12, 13].”
MethodGayam, V. B. R., Mandal, A., Garlapati, P. R., Khalid, M. O., Gill, A. S., & Khalid, M. (2018) · Case Reports in Gastrointestinal Medicine · doi:10.1155/2018/8714390 · Cited by 6
“Moderate hypertriglyceridemia is defined as triglyceride (TG) levels between 200 and 999 mg/dL [5].”
BackgroundSevere hyperchylomicronemia in two infants with novel APOC2 gene mutation
Köse, E., Armağan, C., Kısa, P. T., Önay, H., & Arslan, N. (2018) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2018-0280 · Cited by 8
Clinical whole exome sequencing in severe hypertriglyceridemia
Tada, H., Nomura, A., Okada, H., Nakahashi, T., Nozue, T., Hayashi, K., Nohara, A., Yagi, K., Inazu, A., Michishita, I., et al. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.10.041 · Cited by 6
A Rare Cause of Acute Pancreatitis in a Transgender Female
Shipley, L. C., Steele, D. T., Wilcox, C. M., et al. (2020) · Journal of Investigative Medicine High Impact Case Reports · doi:10.1177/2324709620921333 · Cited by 6
Al‐Sawalha, N. A., Gaugazeh, H. T., Alzoubi, K. H., & Khabour, O. F. (2020) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13493 · Cited by 6
Abdissa, D. (2021) · Nutrition and Dietary Supplements · doi:10.2147/nds.s298870 · Cited by 6
Delayed diagnosis and treatment of extreme hypertriglyceridemia due to rejection of a lipemic sample
Elslande, J. V., Langlois, M. R., Vermeersch, P., Frans, G., der Schueren, B. V., Mertens, A. C., Meijers, B. K. I., Vusser, K. D., & Hijjit, S. (2021) · Biochemia Medica · doi:10.11613/bm.2021.021002 · Cited by 7
“6 mmol/L warrant immediate treatment to reduce TG (3).”
BackgroundHalcox, J. (2013) · Clinical Lipidology · doi:10.2217/clp.13.16 · Cited by 6
Approach to the Patient with Dyslipidemia
Feingold, K. R. (2015) · Europe PMC (PubMed Central) · Cited by 7
A snapshot of lipid levels in the Republic of Ireland in 2017
Agar, R., Markham, C. E., Prendergast, M., Canning, R., Maher, E., Finn, C., Sammon, N., Fall, S., Fallon, N., Hanrahan, E., et al. (2018) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-018-1820-3 · Cited by 6
Determinants of Course of Type 2 Diabetes in Indian Adolescents
Raithatha, D., Sen, P., Dave, C., Yadav, V., Mahapatra, A., Shukla, R., & Bajpai, A. (2024) · The Indian Journal of Pediatrics · doi:10.1007/s12098-024-05157-3 · Cited by 5
“Dyslipidemia was diagnosed as per the Endocrine Society guidelines [13].”
Baass, A. W., Paquette, M., Lam, O., Hofer, K., Collet, J., & McClain, M. R. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.08.012 · Cited by 7
Plasma lipemia: When the blood donor becomes a patient
de Oliveira, M., Antunes, M. B., & Amil, M. (2021) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2021.103294 · Cited by 5
Effects of Lactobacillus paracasei N1115 on dyslipidaemia: A randomized controlled study
Jiang, H., Tan, S., Ning, K., Li, H., Zhao, W., Zhao, A., Zhu, H., Wang, S., Wang, P., & Zhang, Y. (2022) · Journal of Functional Foods · doi:10.1016/j.jff.2022.104956 · Cited by 8
Management der akuten Pankreatitis in der Notaufnahme und Intensivstation
Finkenstedt, A., & Joannidis, M. (2024) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-023-01104-w · Cited by 6
“Bei Triglyze-ridwerten >1000mg/dl (11,3mmol/l) kann die Hypertriglyzerid-ämie als ursächlich für die akute Pankreatitis angesehen werden [5].”
Zou, Y., Yang, Q., Lang, Y., Liu, K., Yuan, J., Yang, J., Chai, Z., Cooper, M. E., & Liu, F. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16056 · Cited by 8
Masson, W. M., Barbagelata, L., Fleitas, M., Herzkovich, N., Kerschner, E., Rossi, E., Siniawski, D. A., Ami, M. V., & Nogueira, J. P. (2023) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000601 · Cited by 6
“There are several cut-off points for triglyceride level to consider “severe hypertriglyceridemia”, which especially consider the risk for pancreatitis (10,11).”
BackgroundPosicionamento Brasileiro sobre Síndrome da Quilomicronemia Familiar – 2023
Izar, M. C. D. O., Santos, R. D., Assad, M. H. V., Chagas, A. C. P., Toledo, A. D. O., Nogueira, A. C. C., Souto, A. C. C. F., Lottenberg, A. M., Chacra, A. P. M., Ferreira, C. E. D. S., et al. (2023) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20230203 · Cited by 9
Hu, Y., Zhang, G., Yang, Q., Pu, N., Li, K., Li, B., Cooper, D. N., Tong, Z., Li, W., & Chen, J. (2023) · Lipids in Health and Disease · doi:10.1186/s12944-023-01875-3 · Cited by 6
“4 mmol/L (> 2000 mg/dL)) by the Endocrine Society [4].”
InfluentialZhu, L., Yuan, L., Wang, T., Zhu, Q., Zhang, Q., Pan, C., Xu, Q., Deng, D., Chen, W., & Chen, J. (2023) · BMC Gastroenterology · doi:10.1186/s12876-023-02951-9 · Cited by 7
“If the TG level was ≥ 22.4 mmol/L, it was defined as very severe hyperlipidemia [8].”
BackgroundInfluentialTan, P., Lu, S., Chen, Q., Ma, H., Kong, W., Huang, X., Yu, C., & Jin, M. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02511-y · Cited by 7
Lipids and cardiovascular disease 3 Triglycerides and cardiovascular disease
Nordestgaard, B. G., & Varbo, A. (2014) · Cited by 5
Novel Strategies for Treating Lifestyle-related Diseases Using Various Approaches
Miyamoto, L. (2016) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.15-00251 · Cited by 5
Metadata
- Authors
- Berglund, L., Brunzell, J. D., Goldberg, A. C., Goldberg, I. J., Sacks, F., Murad, M. H., & Stalenhoef, A. F. H.
- Affiliations
- University of California, Davis (US)
- University of Washington (US)
- Washington University in St. Louis (US)
- Columbia University (US)
- Harvard University (US)
- Mayo Clinic (US)
- Radboud University Medical Center (NL)
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2012-09-01
- Volume
- 97
- Issue
- 9
- Pages
- 2969-2989
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC3431581
- OpenAlex
- W2111416524
- Cited by
- 887
- References
- 206
- Citations by year
- 2026: 55 · 2025: 54 · 2024: 74 · 2023: 62 · 2022: 72 · 2021: 74 · 2020: 83 · 2019: 61 · 2018: 89 · 2017: 50 · 2016: 62 · 2015: 57 · 2014: 48 · 2013: 41
- FWCI
- 47.54
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Funders
- American Heart Association
- European Society of Endocrinology
- National Heart, Lung, and Blood Institute (R01HL045095)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- hypertriglyceridemia, triglyceride levels, fasting triglycerides, cardiovascular risk, pancreatitis, secondary hyperlipidemia, familial hypertriglyceridemia, dyslipidemia, non-HDL cholesterol, lifestyle therapy, fibrate therapy
- MeSH terms
- Exercise Therapy, Humans, Terminology as Topic, Triglycerides, Hypertriglyceridemia, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-08, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-08 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.